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ABSTRACT 
 
Sarcomere is the basic unit of cardiac and skeletal muscle contraction and its proper function requires an 
invariant organization of this structure. Mutations in sarcomeric proteins are known to cause increasing 
number of different cardiac and skeletal muscle diseases. The front line in research on muscle diseases is 
at present to define the genetic background and pathogenesis of these diseases. The potential for 
development of effective therapies depends on elucidation of the molecular and cellular impact of the 
mutations on morphological abnormalities and muscle weakness that accompany pathogenesis.  
  In paper I we identified an unexpected skeletal muscle myopathy in an infant with fatal cardiomyopathy 
due to a homozygous mutation in MyBPC3. The ectopic expression of cardiac MyBPC was restricted to 
abnormal type 1 muscle fibres, indicating that the muscle pathology was caused by a dominate-negative 
effect of mutant MyBPC3.  
  In paper II we addressed the expression profile of a panel of sarcomeric components during myogenesis, 
with a focus on proteins associated with a group of congenital disorders. The analyses were performed in 
cultured human skeletal muscle myoblasts and myotubes. We identified early expression of certain 
isoforms involved in congenital diseases, suggesting the possibility of an early role for these proteins as 
constituent of the developing contractile apparatus during myofibrillogenesis.  
  In paper III we used human tissue-culture cells as a model to investigate the primary trigger for β-
tropomyosin-related myopathies and the basis for the histological changes seen in muscle biopsies of 
patients. Protein localization and pathobiology caused by dominant TPM2 mutations were investigated by 
transfecting human myoblasts and C2C12 with WT and mutant EGFP-fusion β-TM constructs. Abnormal 
aggregation of β-TM variants and their localization within the thin filaments was observed in myoblasts 
and differentiated myotubes. We demonstrated that histopathological phenotypes associated with β-TM 
mutants might be accounted for the variable response to the cellular environment influenced by 
physiological context, in combination with the time course of expression of mutant protein rather than the 
alteration of amino acid itself. Our results confirmed that cell cultures of human skeletal muscle are an 
appropriate tool and environment closer to the reality in human skeletal muscle and more reliably mimic 
the disease conditions.  
  In paper IV we identified and characterized a new human protein aggregate myopathy and 
cardiomyopathy associated with combined mutations in isogenes TRIM63 and TRIM54, encoding muscle 
specific ring finger proteins, MuRF1 and MuRF3, respectively. Our morphological and cellular 
investigation suggested that the disease is caused through impaired organization of the microtubule 
network and sarcomeric M-band proteins. The results from this study have deepened the understanding of 
pathogenesis of a group of sarcomeric myopathies, which is an essential step towards identifying new 
therapeutic targets. 
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1 INTRODUCTION 
1.1 Skeletal muscle satellite cells 
Satellite cells or muscle stem cells derive from the central area of dermomyotome located at the dorsal 
section of the somites of the paraxial mesoderm [1] . The cells have increased size of nuclear with little 
cytoplasmic organelle content [2] localized between the basal lamina and sarcolemma of muscle fibres 
periphery [3] figure (1). Satellite cells are heterogeneous group contain a mixture of stem cells capable of 
self-renew and committed progenitors responsible for postnatal growth, regeneration and homeostasis 
repair [4, 5] [3, 6]. The percentage of stem cells is high in newborns but decreases in number with age 
due to loss of muscle mass “sarcopenia” or muscle wasting caused by muscular dystrophies [1]. 
 
 
 
 
 
 
 
 
 
The satellite cells commence from the quiescent stage due to trigger by trauma, such as injure, 
degenerative disease or weight bearing [3]. The stimulation of myogenic precursors is restrained by 
proximal signals from muscle niche, microvasculature and inflammatory cells [7]. The activated satellite 
cells move outside basal lamina and start to cycle, proliferate, differentiate and fuse with each other or to 
pre-existing myofibres [3, 8]. The process can be summaries as follow, stem cells (fate not acquired) → 
progenitor (fate acquired) → myoblasts (fate acquired, myogenic genes activated) → differentiation → 
myofibres [9]. 
1.1.1 Muscle regeneration 
The regeneration is a multiple wave procedure similar to embryonic muscle development. The process 
begins with embryonic wave initiation, followed by foetal wave and postnatal wave ending by the growth 
of musculature to adult size [10]. However, there are few differences between the embryonic muscle 
development and muscle regeneration, for instance cell niche, anatomy and involvement of regulatory 
genes [9]. The niche of satellite cells regulates the function of the cells during muscle regeneration 
through autocrine, paracrine and endocrine mechanisms [4].  
 
The disturbed myofibre undertakes either total autolysis or local in a process that can be divided into two 
phases, degeneration and regeneration phase [2]. The degeneration phase begins by the premature death 
of cells in muscle fibres (necrosis) with disordered sarcolemma leading to an increase permeability that 
causes escalating level of a muscle protein commonly located to the myofibre cytosol, namely creatine 
kinase (CK). Furthermore, the disrupted sarcolemmal or sarcoplasmic reticulum triggers an influx of Ca2+ 
Figure 1.Schematic diagram of an activated satellite cell in regenerating myofibre 
and a quiescent satellite cell in normal myofibre. 
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2 
causing a loss of Ca2+ homeostasis, leading to the activation of Calpains. The Calpains are calcium 
dependent proteolysis that cleaves myofibrillar and cytoskeletal proteins [2].  
The regeneration phase is a highly orchestrated process ensuring that specific genes are regulated in a 
sequential organized manner. The mechanism involves cell-cell and cell matrix interactions as well as 
extracellular secreted factors including, trophic factors members of EGF family, interleukin-6 (IL-6) 
family of cytokines and nitric oxide [2]. The process of regeneration comprising, activation of satellite 
cells, proliferation, differentiation, up regulation of muscle transcription factors and muscle specific 
genes (figure 2). Additionally, the muscle repair process involves contribution of non-muscle so called 
multipotent cells that include stem cells derived from bone marrow, vessel-associated stem cells, 
neuronal compartment and mesenchyme tissues [2, 10]. 
 
 
 
 
 
 
 
 
 
There are two kinds of transcription factors networks controlling muscle development, the paired-box 
transcription factors and myogenic regulatory transcription factors [10]. The paired-box (Pax) 
transcription factors are family of proteins working upstream of myogenic regulatory transcription factors 
and are characterized by the presence of a paired domain. They are important during development 
through the regulation of cell specification and organogenesis [10]. In several Pax proteins including 
Pax3 and Pax7, contain a second highly conserved motif, the homeodomain [11]. Pax3 expressed during 
embryonic development while Pax7 expressed in postnatal development in the resident progenitors 
population [3].  
The myogenic regulatory transcription factors (MRFs) are a superfamily of basic helix loop helix (bHLH) 
transcriptional regulators with over 400 members that are activated during developmental processes 
including myogenesis and neurogenesis [11]. Each member of this family has a distinct role [11]. For 
example, the activation of MYF5 promotes satellite cells self-renewal, regulates proliferation rate and 
homeostasis [2], while the activation of MYOD promotes differentiation [2]. The expression of MYOG 
and MRF4 regulates the terminal differentiation program [2]. MRF4 plays a role in determining fibre 
phenotype in postnatal life, particularly in maintaining slow phenotype [12].  
1.1.2 Myofibrillogenesis  
The myofibrillogenesis procedure requires the assembly of structural and regulatory molecules into the 
sarcomeric contractile units.  This involves the function of many different proteins together to convert the 
molecular interaction of actin and myosin into the mechanical force and movement. The 
myofibrillogenesis process involves huge alterations of myogenic cells (myoblasts) cytoarchitecture and 
protein expression. The myoblasts start migration, elongation, extensive cytoskeletal reorganization; 
Figure 2. A model of the main events of regeneration in skeletal muscle. 
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3 
membrane alterations and cytoskeleton proteins changing from non-muscle-specific to muscle-specific 
protein isoforms. Eventually, the myoblasts either fuse with existing damaged fibres for repair to one 
another for new fibre formation of mature multinucleated cell [13].   
There are mainly two models proposed by Holtzer and Sanger for the formation of contractile myofibrils. 
Holtzer and colleagues suggested that precursors of mature thin and thick filaments form independently 
in the myoplasma of developing muscle and at the late stages of development proceed along common 
filaments [14, 15]. Sanger and colleagues proposed a model were precursors of thin and thick filaments 
form along the same structure, which together develop into mature sarcomeres [14, 16].    
1.1.3 Primary culture of human myogenic cells 
There are several myogenic cell lines such as rat L6, L8, mouse C2C12, and murine MM14 myoblasts 
cell lines that have been frequently used for various in vitro studies for example, the characterization of 
muscle development, a model for human muscle disorders, or for the development of cell- based 
therapies for muscle diseases. The human myogenic cells (myoblasts) have been used in similar studies 
but in a limited manner. The limitation is due to the difficulty of isolating a pure primary human 
myogenic cells (myoblasts) [7]. The human primary myogenic cultures usually prepared from 
mononucleated cells dissociated from the whole muscle whereby the satellite cells are released from their 
niche. The cells are detached from the muscle tissue enzymatically and mechanically. The single cells are 
removed by filtration and plating. Furthermore, due to the presence of non-myogenic mononuclear cells 
in human skeletal muscle, including adipocytes, fibroblasts and lymphocytes different methods are used 
to isolate a purer population of myoblasts. Therefore for more specific and efficient isolation of 
myoblasts, Webster et al. utilized fluorescence-activated cell sorting (FACS) to positively select for cells 
expressing the human neural cell adhesion molecule (NCAM), that is a cell surface antigen, or melanoma 
cell adhesion molecule (MCAM), or the vascular cell adhesion molecule 1 (V-CAM-1)[7]. 
Cultured myoblasts go through three morphological and biochemical distinct developmental stages. The 
first stage is proliferation, proceeding through at least one round of cell division with high motility rate 
compared to other cultured cells.  The cultured myoblasts have limited proliferation capacity due to sub-
optimal levels of growth factors in the growth medium [17]. The second stage is the migration and 
alignment of single myoblasts into long chains followed rapidly by membrane fusion and the formation 
of the multinucleate myotubes. Finally, the third stage is the development of the contractile machinery.  
 
The primary myogenic culture has its advantages and drawbacks. An advantage could be the ability of 
studying the morphological and functional changes occurring during myogenesis which are well 
characterized and can be observed in primary myogenic culture due to the rapid formation of long 
multinucleated myotubes from a layer of mononuclear cells (figure 3). A drawback could be that the 
living functional cells are in a defined environment outside the body and thus the cells are removed from 
a complex environment of changeable cell populations and variable volumes of extracellular fluids that 
have a great influence on the cells [7]. 
 
 
 
 
 
 
 
4 
 
 
 
 
 
 
 
 
 
1.2 Myofibres 
The myofibres are long cylindrical structure surrounded by a plasma membrane, sarcolemma and contain 
up to several thousands of nuclei located peripherally beneath sarcolemma. Muscle fibres are 10 µm in 
diameter and few millimetres to several centimeters long. Each fibre composes of myofibrils, and 
cytoskeletal network, that anchor the contractile fibrils to the sarcolemma. Myofibrils are built of 
repeating contractile units known as sarcomeres. The sarcomere is the most highly ordered 
macromolecular structure in eukaryotic cells [18] built of thick and thin filaments. This arrangement is 
responsible for the cross-striated banding pattern observed under light and electron microscopy.  
1.2.1 Sarcomere 
The sarcomere is between 2,0 - 2,5 µm in length with the Z-disc at their ends and where the thin actin 
filaments of opposite directions are linked together by alpha-actinin dimers [19]( figure 4). There are 
several proteins located at the Z-disc such as, alpha-actinin, which is an F-actin cross-linking protein 
Figure 3. Microscope view using 10x objective of human myoblasts (A) and 
myotubes after 30 days of differentiating (B) in tissue culture. Scale bar = 200 µm 
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associated with the barded end of the thin filaments. The alpha-actinin is a homodimer made of two 
elongated subunits with antiparallel orientation and a basic structure similar to that of spectrin and 
dystrtophin. Another protein located at the Z-disc is CapZ protein that belongs to a member of a family of 
heterodimeric actin binding proteins called capping proteins present in most tissues that bind to the 
barded ends of actin filaments. Z-disc is located in the  
 
 
 
 
 
 
 
 
middle of the I-band, which appears lighter in a light microscope and contains mainly actin filaments 
whereas the A-band appears darker due to polymers of myosin molecules. The A-band divided by a light 
region called H-band. The midline of H-band is the M-line where the thick filaments are anchored by 
several myosin-binding proteins. The M-line contains other proteins such as myomesin, muscle specific 
calpain 3, and muscle specific RING finger protein 1(MuRF1). The MuRF1, MuRF2 and MuRF3 
proteins are highly homologous ring finger proteins. These proteins have various physiological functions 
in skeletal and heart muscles [20]. They bind to sarcomeric proteins, cytoskeletal proteins, enzymes 
involved in ATP production, regulators of nuclear transcription, which in turn modify nuclear 
translocation, gene expression, and subcellular targeting. The MuRFs proteins play an important role in 
linking myofibril components with microtubules, intermediate filaments and nuclear factors [21]. 
Moreover, they function as E3 ubiquitin ligases in ubiquitin mediated muscle protein turnover to regulate 
protein degradation and gene expression in muscle tissues [21, 22]. Furthermore, MuRF1 and MuRF3 are 
E3 ubiquitin ligases that catalyse the degradation of slow/beta MyHC and MyHC IIa via the UPS in 
striated muscles [23]. MuRF1 detected at the Z-line and soluble form in the cytoplasm. MuRF2 is 
expressed in at least four isoforms in striated muscles and also binds to titin and then disappears as 
mature myofibrils form [24]. MuRF3 co-localizes with microtubules and with the sarcomeric Z-line and 
M-line. It is suggested that MuRF2 and MuRF3 are associated indirectly with titin via MuRF1 and the 
localization of MuRF1 to Z-lines has been speculated to be the result from coiled-coil heterodimerization 
with MuRF3.  
1.2.2 Thin filament 
The major components of the thin filaments are actin, tropomyosin, and the troponin complex. The 
globular actin monomers (G-actin) form a double-helical filament (F-actin) that interacts with myosin 
with NH2-terminal. There are two actin isoforms in sarcomeric muscles, alpha-skeletal and alpha-cardiac 
actin encoded by two distinct genes. The structure of the two isoforms is conserved during vertebrate 
evolution from reptiles to birds and mammals. In humans they are co-expressed in adult skeletal and 
cardiac muscles. Tropomyosin molecules are assembled in a head-to-tail fashion as homodimers or 
heterodimers in the major groove of the actin filament forming a filament associated with actin double 
helix. Tropomyosins are elongated dimeric proteins with subunits consisting of alpha-helical coiled- coils 
and arranged in parallel orientation. There are three isoforms, α, β and γ, encoded by TPM1, TPM2 and 
Figure 4. Schematic diagram of a single sarcomere. 
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TPM3 respectively. The relative ratio of alpha to beta-subunits is higher in fast compared to slow muscles 
and varies among different fast muscles. Each tropomyosin dimer spans seven actin monomers, and each 
troponin complex is also associated with seven actin repeats. The troponin complex consists of three 
subunits TnC, the Ca2+ binding subunit, TnI, the inhibitory subunit and TnT, the tropomyosin subunit. 
Troponin constitutes the Ca2+ sensitive switch that regulates the contraction of striated muscle fibres. The 
elongated NH2-terminal half of TnT extends for a considerable length along tropomyosin and spans the 
head to tail overlap of tropomyosin. There are two TnC genes, coding for TnC-fast and TnC-slow/cardiac 
isoforms, and three TnI genes coding for TnI-fast, TnI-slow, and TnI-cardiac isoforms. There are three 
TnT genes each of which generates a large number of transcripts by alternative splicing [24-27].   
1.2.3 Thick filament 
 
The thick filament is the bipolar polymer of the motor protein myosin that interacts with actin to produce 
force and sarcomere/muscle shortening. The thick filament contains myosin, several myosin binding 
proteins MyBPC, M- protein, and myomesin. The sarcomeric myosin conventional class II myosin has 
two heads and long tails connected by a neck region and consist of two heavy chains. Myosin is a 
molecular motor that generates mechanical force from ATP hydrolysis, through the interaction of myosin 
globular head domain (myosin sub-fragment 1 S1) with actin filaments. Myosin composed of one pair 
myosin heavy chain (MyHCs) and two pairs of light chains (MyLCs). Human sarcomeric myosin heavy 
chain (MyHC) isoforms encodes by a multigene family and their expression is developmentally 
regulated. There are eight known sarcomeric MHCs isoforms, five of which expressed in skeletal muscles 
fibres. The embryonic MyHCemb and neonatal MyHCneo, are two isoforms expressed during embryonic 
and perinatal development; MyHC I or β/slow MyHC, expressed in slow skeletal muscle fibres; MyHC 
IIa and MyHC IIx are fast isoforms expressed in fast skeletal muscle fibres. All myosin-associated 
proteins have a characterized structure of two types of internal domains of 100 amino acids each domain. 
These domains are homologous to either immunoglobulin (Ig) or fibronectin (Fn) type III repeats and 
consist of seven beta-strands arranged in two sheets. There are three major isoforms of MyBPC slow, fast 
and cardiac each contains several Ig and Fn like repeats and binding sites for myosin that are located in 
the COOH-terminal. The M-protein and myomesin are both located at the M-line and bind the COOH-
terminal of the myosin molecules. The two proteins are similar in size and consist of the same number 
and sequence of repeated Ig and Fn-like modules [24-27].  
 
 
 
 
 
 
 
 
 Figure 5. Schematic diagram showing the major components of the sarcomere. 
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1.2.4 Titin 
Titin is a giant protein encoded by a single gene and extends from Z-disc to the M-band within the 
sarcomere. Titin comprises an inextensible segment at the level of the A-band and an elastic segment at 
the level of I-band. At the A band, titin binds myosin at the level of the MHC rod and C protein. The 
COOH-terminal of titin is anchored to the M band and binds both M protein and myomesin. The major 
part of titin mass consists of repeating immunoglobulin Ig and fibronectin-III (FN-III) domains. It 
contains 244 recognizable beta-sheet domains of which 112 have been assigned to the immunoglobulin 
superfamily and 132 to the fibronectin type III superfamily. Both Ig and FN-III domains provide binding 
sites for diverse proteins, including myofibrillar, membrane components, enzymes and signaling 
molecules [24-27].  
1.2.5 Nebulin 
Nebulin is a giant protein presents in skeletal muscle and extends along the thin filaments as a single 
polypeptide from the Z-disk to the free end of the thin filament. The COOH- region attached to the Z-disc 
and interacts with alpha-actinin. Nebulin modules have an alpha helical conformation that is probably 
stabilized by its interaction with actin [27]. 
1.3 Congenital myopathies  
The congenital myopathies are a class of muscle diseases present at birth defined by distinctive 
morphologic abnormalities in the skeletal muscle. The disease is usually inherited in an autosomal 
dominant or autosomal recessive fashion, but there are some sporadic cases. The cap disease and 
nemaline myopathy (NM) are congenital myopathies. The term cap disease is used to describe the 
abnormal peripheral crescents in the majority of muscle fibers. Caps are present in 20%-70% of muscle 
fibres, with a higher proportion of fibres involved in the more severely affected patients. There is a sharp 
delineation between the cap and the adjacent regions of the fibre with normal ultra-structure. These 
findings have prompted speculation that caps result from failure of myoblast fusion and abnormal protein 
synthesis during myogenesis [28].  
 
Nemaline myopathy (NM) is characterized by the presence of rod-shaped structured in the muscle fibres. 
The smallest rods (<1µm long) palisade in the plane of the Z discs. The larger rods are separated from 
myofibrils and accumulate randomly or in clusters, especially under the sarcolemma and round nuclei. 
The fibre type 1 predominance in NM is associated with abnormally high expression of fetal myosin and 
co-expression of fast and slow myosin in some muscle fibres [28].  
 
Distal myopathy is a second class of muscle diseases that is either inherited or sporadic muscle disorders 
characterized pathologically by myopathic changes in skeletal muscles [28].   
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2 AIMS OF THE STUDY 
 
§ To describe the clinical, morphological and genetic characteristics of a new unexpected 
myopathy associated with a mutation in cardiac isoform of myosin binding protein C. 
§ Using cultured human skeletal muscle cells to investigate the expression profile of a panel of 
sarcomeric components during myoblast proliferation and myotube development with a focus on 
proteins associated with a group of congenital disorders.  
§ To assess whether cultured human skeletal muscle cells are appropriate tool to study 
developmental stages of myofibrillogenesis. 
§ To investigate whether cultured human skeletal muscle cells can be used as an efficient host for 
gene transfer.  
§ To use human cultured skeletal muscle cells as a cellular model to examine the phenotypes of 
myopathy-related beta-tropomyosin mutants.  
§ To compare human and mouse cultured skeletal muscle cells as cellular models to investigate the 
behavior of beta-tropomyosin mutants.  
§ To describe the clinical, morphological and cellular characteristics of a new human protein 
aggregate myopathy and cardiomyopathy associated with combined homozygous null mutation 
in TRIM63 and a heterozygous missense mutation in TRIM54. 
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3 MATERIALS AND METHODS 
 
Muscle biopsy (Paper I & IV) 
A biopsy specimen obtained from the quadriceps muscle from an infant patient at the age of two months. 
An open muscle biopsy specimen was obtained from the biceps brachii from a 55 years old man. The 
samples were instantly frozen in isopentane chilled by liquid nitrogen and stored at -80°C. 
Primary human muscle cells and C2C12 (Paper II-IV) 
Healthy controls of similar age were used in paper I. Enzymatically isolated human satellite cells from a 
healthy donor were obtained from MYOSIX through a collaborative program with Association Francaise 
contre les myopathies (AFM).  Nine standardized batches of these cells were used in paper II-IV. Skeletal 
muscle biopsy obtained from the patient was used to isolate muscle satellite cells and cultured as 
previously described [29]. In addition, a mouse cell line C2C12 myoblasts purchased from American 
Type Culture Collection (ATCC) was used in paper III.  
Electron microscopy (Paper I & IV) 
A small piece of the biopsy tissue was fixed in 2% glutaraldehyde and post-fixed with 1% osmium 
tetroxide and finally embedded in araldite. The ultrathin sections were stained with uranly acetate and 
lead citrate to be examined with electron microscopy. 
Morphological and histochemical analyses (Paper I & IV) 
Cryostat sections of frozen skeletal muscle specimens were stained with haematoxylin-eosin, Gomori 
trichrome, PAS and congo red. In addition, enzyme histochemistry performed for NADH-tetrazolium 
reductase and myofibrillar ATPase at different pH. 
DNA analyses (Paper I & IV) 
§ Genomic DNA  
DNA was extracted from frozen skeletal muscle and or peripheral blood.  
§ DNA Sequencing 
Mutation screening was performed for MYBPC3 in paper I, TRIM63 and TRIM54, in addition to 
MYH7, ACTA1, TPM2, TPM3, TNNT1, ACTN3, ACTN2 and FHL1 in paper IV. In addition, 
sequencing of TRIM63 exon 5 was performed in 200 control DNA samples.  
§ Restriction fragment length polymorphism (RFLP) analysis 
The mutation of TRIM54 was screened for the patient and eight members of his family, in 
addition to 100 Swedish and 100 Spanish controls in paper IV.  
RNA analyses (Paper I, II & IV) 
§ cDNA synthesis 
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Total RNA was extracted from skeletal muscle tissue in paper IV, using the RNeasy Mini Kit & 
I.  In addition, total RNA was extracted from primary muscle cultured-cells in paper II and IV, 
using RNeasy Plus Mini Kit (Qiagen, Hilden, Germany). Synthesis of first-strand complementary 
DNA (cDNA) was performed from RNA using Ready-To-Go You-Prime First-Strand Beads. 
§ Polymerase chain reaction (PCR) and sequence analyses 
Polymerase chain reaction (PCR) performed on cDNA from patients in order to confirm the 
appearance of the mutation at the transcript level for MYBPC3 in paper I and TRIM63 and 
TRIM54 in paper IV. PCR analysis was performed on cDNA extracted from cultured cells in 
paper II and IV. The expression of a panel of genes including; desmin (DES), titin (TTN), MyHC 
isoforms (MYH1, MYH2, MYH3, MYH4, MYH7 and MYH8), α-cardiac actin (ACTC) and α -
skeletal actin (ACTA1), tropomyosin isoforms (TPM1, TPM2 and TPM3), troponin T isoforms 
(TNNT1, TNNT2 and TNNT3), troponin I isoforms (TNNI1, TNNI2 and TNNI3), skeletal muscle 
myosin-binding protein C isoforms (MYBPC1, MYBPC2) and cardiac myosin-binding protein C 
(MYBPC3), myogenic factor 5 (MYF5), myogenic differentiation 1 (MYOD1) and myogenin 
(MYOG) was assessed by PCR and sequence analyses in paper II. The nucleotide sequence 
determination was carried out by cycle sequencing using an ABI 3730xl DNA sequencer (GATC 
Biotech AG, Konstanz, Germany). 
 
Protein analyses (Paper I-IV)  
§ Gel electrophoresis, immunoblotting and chemiluminescent analysis 
Protein samples were extracted from skeletal muscle tissue from a control, a patient with critical 
ill intensive care unit (ICU) and the patient in paper IV. Proteins from cultured cells were 
obtained using the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany), after RNA was recovered 
from the cell lysate, by acetone precipitation. The protein extracts from either skeletal muscle 
tissue or cultured cells were separated by 8% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) after heating to 100 °C for two minutes in Laemmli Buffer. 
Separated proteins were transferred to polyvinylidene difluoride membranes. The membranes 
were incubated with primary antibodies against MuRF1, MuRF3 and α-tubulin, and HRP-
conjugated secondary antibodies using chromogenic Western Blot Immunodection kit. The 
chemiluminescent analysis was performed using anti-sarcomeric actin as primary antibodies 
detected with horseradish peroxidase-labeled secondary antibodies. The immunoreaction was 
detected with SuperSignal West Femto Chemiluminescent Substrate (Pierce) and captured by 
ImageQuant™ software in LAS 4000 CCD camera.  
§ Immunohistochemical analysis   
The analysis was performed on frozen skeletal muscle sections, which were incubated with 
antibodies against cardiac MyBPC, embryonic and fetal MyHCs and α-cardiac actin in paper I. In 
paper IV, a panel of antibodies against sarcomeric and cytoskeletal proteins were used including 
slow and fast myosin heavy chains, myotilin, filamin C, desmin and αB-crystallin. The 
immunohistochemistry analysis was performed on proliferating myoblasts and myotubes. The 
cells were incubated with primary antibodies (Table 1) followed by incubation with 
EnVision™Flex/HRP and visualized by the indirect peroxidase-antiperoxidase complex method 
using diaminobenzidine as a chromogen. Nuclei were counterstained with hematoxylin in paper 
II. 
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§ Immunofluorescence analysis 
In papers II, III, IV cells fixed in 4% formaldehyde (methanol-free 16% formaldehyde solution), 
free aldehyde groups were blocked with 50mM NH4Cl, permeabilized in 0,1% Triton X-100. 
Cells were incubated with primary antibodies (Table 2) for 1 h in a humidified chamber at 37°C, 
followed by incubation with secondary antibodies for 1h in the dark. Finally, the slides were 
mounted with a coverslip using Prolong Gold antifade reagent with DAPI to highlight cell nuclei. 
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PRODUCT 
NAME 
PRODUCT 
CODE 
ANTIGE
N 
DILUTION  
IMMUNOCYTO 
CHEMISTRY/ 
IMMUNOFLUORESCENC
E 
DILUTION 
SECONDARY 
ANTIBODY 
COMPANY 
Mouse 
monoclonal to 
desmin 
M0760 Desmin 1:100 1:1000 Anti-mouse Dylight 549 DakoCytomation 
Mouse 
monoclonal 
[F5D] to 
myogenin 
Ab1835 Myogenin 1:50  Abcam plc 
Mouse 
monoclonal to 
troponin T, fast 
NCL-TROPT TNNT 1:20  NovoCastra™Lyophilized 
Mouse 
monoclonal to 
titin 
3010-S Titin 1:50  BioCytex 
Mouse 
monoclonal to 
sarcomeric 
actin 
M0874 
Alpha-
skeletal 
actin 
1:10 1:1000 Anti-mouse Dylight 549 DakoCytomation 
Mouse 
monoclonal 
cardiac actin 
M622709 
Alpha-
cardiac 
actin 
1:20 1:1000 Anti-mouse Dylight 549 
Nordic Biolabs 
Bioreagents 
Mouse 
monoclonal to 
myosin heavy 
chain, 
(developmental
) 
NCL-MHCd 
MyHC-
embryoni
c 
1:10 1:1000 Anti-mouse Dylight 549 
NovoCastra™Lyophilize
d 
Mouse 
monoclonal to 
myosin heavy 
chain, 
(neonatal) 
NCL-MHCn MyHC-neonatal 1:10 
1:1000 Anti-mouse 
Dylight 549 
NovoCastra™Lyophilize
d 
Mouse 
monoclonal to 
myosin heavy 
chain, (slow) 
NCL-MHCs MyHC-slow 1:250  
NovoCastra™Lyophilize
d 
Mouse 
monoclonal to 
myosin heavy 
chain, (fast) 
NCL-MHCf MyHC-fast 1:120  
NovoCastra™Lyophilize
d 
Mouse 
monoclonal to 
MYH2  
N2.261 
MyHC-
fast 
IIa+slow 
1:120 1:1000 Anti-mouse Dylight 549 
Santa Cruz 
Biotechnology 
Mouse 
monoclonal to 
sarcomeric 
tropomyosin 
T9283 TPM 1:100  Sigma-Aldrich 
Rabbit 
polyclonal to 
beta 
tropomyosin  
ARP48224T10
0 TPM2 1:120  Aviva Systems Biology 
Rabbit 
polyclonal to 
myosin binding 
protein C, 
(slow) 
HPA021004 MYBPC1-slow 1:50  Sigma-Aldrich 
Rabbit 
polyclonal to 
myosin binding 
protein C, 
(fast) 
SAB2101539 MYBPC2-fast 1:100  Sigma-Aldrich 
Mouse Ab8293 TNNI- 1:500  Abcam plc 
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monoclonal 
[12F10] to 
skeletal muscle 
troponin I, 
(slow) 
slow 
Mouse 
monoclonal 
[2F12A11] to 
skeletal muscle 
troponin I, 
(fast) 
Ab119943 TNNI- fast 1:200  Abcam plc 
Mouse 
monoclonal 
[284(19C7)] to 
cardiac 
troponin I  
Ab19615 TNNI- cardiac 1:500  Abcam plc 
Mouse 
monoclonal 
T12 to Z-disc 
titin 
 Z-disc 1:20 
Polyclonal  Anti-
Mouse 
Immunoglobulins/FIT
C 1:1000 
 
Fürst et al., 1988 
Mouse 
monoclonal T3 
to A/I junction 
titin 
 A/I junction 1:5 
Polyclonal  Anti-
Mouse 
Immunoglobulins/FIT
C 
1:1000 
Fürst et al., 1988 
Mouse 
monoclonal 
T30 to A-band 
titin 
 A-band 1:5 
Polyclonal  Anti-
Mouse 
Immunoglobulins/FIT
C 1:1000 
 
Fürst et al., 1989 
Mouse 
monoclonal 
T51 to M-band 
titin 
 M-band 1:5 
Polyclonal  Anti-
Mouse 
Immunoglobulins/FIT
C 1:1000 
 
Obermann et al., 1996 
Table 1: Antibodies used for immunocytochemical and immunofluorescence analyses. 
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Antigen 
Species Company Ref Dilution 
 
IH 
muscle 
sections 
IF muscle 
sections 
IF cell 
culture 
WB 
MuRF1 Goat Abcam ab4125  1:250  1:200 
MuRF1 Mouse Abcam ab57865  1: 250   
MuRF1 Rabbit Santa Cruz Sc-32920   1:50 1:50 
MuRF2 Goat Santa Cruz Sc-49457   1:50  
MuRF3 Goat Abcam ab4351  1:50 1:50  
Alpha-tubulin Rabbit Abcam ab 4074  1:50 1:1000  
Titin T12 (Z-
disc) Mouse  
Fürst et al., 1988  Undiluted 1:20  
Titin T3 (A/I 
junction) Mouse  
Fürst et al., 1988  Undiluted 1:5  
Titin 30 (A 
band) Mouse  
Fürst et al., 1989  Undiluted 1:5  
Titin 50 (M 
band) Mouse  
Obermann et al., 1996  Undiluted 1:5  
Myomesin 
(BB78) Mouse  Vinkemeier et al 1993  1:5 1:5 
 
M protein 
(AA259) Mouse  Vinkemeier et a.1993  1:2  
 
TNNI1 Rabbit Abcam ab85087  1: 250   
Tropomyosin 3 Sheep Abcam Ab78609  1: 200   
Slow myosin Mouse Novocastra NCL-MHCS 1: 50    
Fast myosin Mouse Novocastra NCL-NHCS 1: 50    
MyHC-fast 
IIa+slow Mouse 
Developmental 
studies hybridoma 
bank, Iowa 
N2.261   
1.120  
α-sarcomeric 
actin Mouse 
DakoCytomation     1:500 
Desmin Mouse DakoCytomation  1: 50  1:100  
Myotilin Mouse Novocastra NCL-myotilin 1: 100    
Filamin C Mouse  RR90 (13 )  1:25   
αB-cristallyn Rabbit Novocastra NCL-ABcrys 1: 500    
Telethonin Goat Santa Cruz SC-8726  1:500   
α-actinin Mouse Sigma A-7811  1: 800 1:3000  
FHL-1 Rabbit Abcam ab49241  1: 500   
Ubiquitin Rabbit DakoCytomation Z-458 1: 100    
     Table 2: Antibodies used in paper IV 
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§ Light/Fluorescence and Confocal microscopies 
Immunoreactivity was analyzed by light/fluorescence microscopy using the Zeiss Axio Observer 
microscope (Carl Zeiss AG, Germany) equipped with 10x, 20x, 40x and 63x oil objectives in 
paper I-IV. Confocal microscopy Zeiss LSM 510 Meta or a LSM 700 inverted Axio Observer.Z1 
microscope were used in paper III and IV. 
Cell culture (Paper II, III and IV) 
§ Myoblasts and differentiation 
Isolated satellite cells from skeletal muscle were plated on chamber slides using Dulbecco’s 
modified Eagle’s medium (DMEM), supplemented with various factors needed for proliferation 
of cells in culture.  
For differentiation, cells were replenished at 85%-90% confluence with DMEM medium, 
supplemented with 5% horse serum and further incubated in this medium from 1 day up to 48 
days. The medium was changed three times a week. 
§ Generation of the enhanced green fluorescent protein (EGFP)-tagged  
The wild-type TPM2 (paper III) and wild-type TRIM63 (paper IV) constructs were generated 
through amplification of TPM2 and TRIM63 cDNA fragments from reverse transcribed human 
skeletal muscle RNA using specific primers introducing XhoI (5’) and EcoRI (3’) restriction 
sites. PCR products were cloned into a PCRII-Blunt-TOPO-vector (Invitrogen, Carlsbad, CA, 
USA) according to the manufacturer’s instructions. Gel purified TPM2/ TRIM63 fragments with 
XhoI (5’) and EcoRI (3’) restriction sites were subcloned into the XhoI and EcoRI restriction sites 
of the enhance green fluorescent protein (pEGFP-N1) to generate WT-TPM2EGFP and WT-
TRIM63EGFP constructs. All TPM2 mutant constructs were generated in the pEGFP-N1 backbone 
through site-directed mutagenesis and cloning into E.Coli in paper III. The wild WT-TRIM54EGFP 
and p.D106N-TRIM54EGFP mutant constructs were generated by amplifying TRIM54 from reverse 
transcribed patient skeletal muscle RNA using the same restriction sites and method as described 
above.  
§ Transfection of cells 
C2C12 and human myoblasts in paper III and myoblasts in paper IV were plated on chamber 
slides in medium without antibiotics one day prior to transfection. Cells were transfected at 
85%-90% confluence using Lipofectamine2000. The cells were incubated overnight at 37°C in 
humidified 5% CO2 atmosphere.  
 Diagram presentation of phenotypes (III) 
The percentages of the phenotypes were presented in a diagram of all TPM2 mutant constructs expressed 
in both human and C2C12 cells before differentiation and after differentiation.   
Multiple sequence alignment (IV) 
The entire amino acids of beta tropomyosin in human and mouse were aligned using ClustalW in paper 
III. Residues within MuRF family domain (MFD) of human and mouse MuRF isogenes were aligned 
using ClustalW in paper IV.  
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Web-addresses (I -IV) 
ClustalW (http://www.ebi.ac.uk/Tools/msa/clustaw2/) 
Exome Variant Server, NHLBI Exome Sequencing Project (ESP), Seattle, WA 
(http://evs.gs.washington.edu/EVS/) 
NCBI BLAST (http://www.ncbi.nlm.nih.gov/BLAST/) 
GenBank accession numbers (I -IV) 
MYOD1     NM_002478 
MYF5        NM_005593 
MYOG       NM_002479 
TPM1        NM_001018005 
TPM2        NM_003289 
TPM3        NM_152263 
ACTA1       NM_001100 
ACTC        NM_005159 
DES           NM_001927 
TTN           NM_133379 
TNNT1      NM_001126132 
TNNT2      NM_000364 
TNNT3      NM_006757 
TNNI1       NM_003281 
TNNI2       NM_001145841 
TNNI3          NM_000363 
MYBPC1      NM_206821 
MYBPC2      NM_004533 
MYBPC3      NM_0000256 
MYH1           NM-005963 
MYH2          NM_001100112 
MYH3          NM_002470 
MYH4          NM_017533   
MYH7          NM_000257 
MYH8          NM_002472 
TPM2           NM_009416 
TRIM63        NM_032588 
TRIM54        NM_187841 
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4 RESULTS AND DISCUSSIONS 
              Paper I: Unexpected myopathy associated with a mutation in MYBPC3 and misplacement   
of the cardiac myosin binding protein C. 
Muscle morphology 
Muscle biopsy from an infant at the age of two months showed myopathic changes with numerous small 
fibres and the expression of slow/β-cardiac myosin heavy chain (MyHC) protein in addition to the 
presence of cardiac isoform of MyBPC. The expression of α-cardiac actin (skeletal muscle developmental 
isoform of actin) was detected in few of the small fibres. Disorganization of the sarcomeres and partial 
depletion of thick filaments were the features in these small fibres revealed by electron microscopy. 
These small fibres were neither regenerating nor immature fibres because of the negative staining for 
embryonic and fetal MyHC proteins as in healthy controls of similar age.  
Genetic findings 
Genomic DNA from the patient was used to amplify and analyse the entire coding sequence of MyBPC3. 
A homozygote null mutation c.2882C→T was identified. In addition, the mutation was identified at the 
transcript level.  
Discussion 
We reported a fatal cardiomyopathy and an unexpected skeletal muscle myopathy in an infant due to a 
homozygous mutation in MyBPC3. The expression of the mutant gene was detected at the transcript level 
in skeletal muscle of the patient.  The expression of cardiac MyBPC was restricted to small, abnormal 
type 1 muscle fibres indicating that the muscle pathology was caused by a dominate-negative effect by 
ectopic expression of mutant MyBPC3. Although, the reason for ectopic expression of cardiac MyBPC 
remains unknown either alteration of a regulatory sequence by the mutation or existence of a second 
mutation of a regulatory protein in trans might be speculated. Notably, there was no general up-regulation 
of cardiac muscle protein isoforms. 
Paper II: Expression profiles of muscle disease-associated genes and their isoforms during 
differentiation of cultured human skeletal muscle cells. 
RNA expression and sequence analysis 
The expressions of transcript of MRFs including MYOD1, MYF5 and MYOG, which regulate the 
expression of muscle specific genes, were detected in human muscle cell cultures both in proliferating 
myoblasts and multinucleated myotubes after 6 days of differentiation (D6).  In addition, the expression 
of a panel of sarcomeric transcripts were detected in both proliferating myoblasts and differentiated.  
Furthermore, the expression of all investigated transcripts was confirmed by sequence analysis. 
Immunocytochemistry and immunofluorescence analyses 
The myogenic identity and stage of differentiation of the mononucleated myoblasts were examined by the 
expression of desmin and myogenin, respectively. The immunocytochemistry and immunofluorescence 
analyses revealed the expression of many proteins involved in muscle diseases, including beta-
tropomyosin, slow TnI, slow MyBPC, cardiac TnI in human mononucleotide myoblasts. In addition, our 
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culture technique resulted in the development of striated myotubes and the expression of adult isoforms 
of the sarcomeric proteins. The mature sarcomeric cross striated pattern of the myofibrils in our cell 
culture was revealed by a panel of titin antibodies (Z-disc, A/I- junction, A-band and M-band). As an 
indication of a successful cell differentiation system, a subset of multinucleated myotubes developed into 
myofibre-like cells with peripheral nuclei. 
Discussion  
In the previous studies, mammalian or avian cultured myocytes have been used as an experimental model 
to analyze the expression of myofibrillar proteins during myogenesis in order to understand the 
mechanisms involved during myofibrillogenesis [30-35]. However, we used cell cultures of human 
skeletal muscle to study developmental stages of myofibrillogenesis. Our studies on human myoblasts 
revealed an early expression of beta-tropomyosin, slow TnI, slow MyBPC, cardiac TnI, which may 
indicate an early role for these proteins as constituent of the developing contractile apparatus during 
myofibrillogenesis. In turn, this may suggest that in disease states the mechanisms of pathogenesis for 
each of the mutated sarcomeric proteins might be reflected by altered expression patterns, and/or 
disturbed assembly of cytoskeletal, myofibrillar structures and muscle development.  
 
Paper III: Phenotypes of myopathy-relate beta-tropomyosin mutants in human and mouse 
tissue cultures. 
The histological behavior of five β-TM mutants associated with different morphological features was 
assessed by transfection studies in human and mouse cultured myoblasts and myotubes.  The mutations 
investigated were, the E41K mutation associated with a congenital myopathy characterized by either cap 
structures or accumulation of nemaline rods, the K49del, G53ins and N202K mutations associated with 
the appearance of cap structures and abnormal coarse-meshed intermyofibrillar network and the E122K 
mutation which is linked to a non-specific congenital myopathy and type 1 fibre predominance. We were 
able to transfect human myoblasts relatively easy with high efficiency and each experiment was repeated 
at least ten times. The filamentous actin was stained with phalloidin to examine the integration and 
localization of mutant β-TM into endogenous action. Both fluorescent and confocal microscopies were 
used to examine the efficiency, morphology and cytoplasmic distribution of wild-type and mutant β-TMs. 
Furthermore, we were able to successfully differentiate transfected human mayoblast into mature 
myotubes with elongated shape and multiple nuclei and sarcomeric pattern. 
Phenotypes observed in human cells transfected with mutant β-TMEGFP 
While the wild-type β-TM showed good incorporation into the stress fibres in myoblasts and sarcomeric 
thin filaments in myotubes, various phenotypes were observed in human myoblasts and myotubes 
transfected with mutant β-TMs. The E41K mutation induced a remarkable levels of diffuse localization 
and reduce incorporation in myoblasts, a perinuclear aggregates was the dominate phenotype in 
myotubes. The K49del- and E122K-β-TMEGFP showed similar behaviors in transfected myoblasts and 
myotubes. The mutants were incorporated into clouds in random locations in the nucleus and 
cytoplasmic, in addition to occasionally formation of intranuclear rod-shaped structures. Although the 
mutant K49del-β-TMEGFP and E122K- β-TMEGFP showed good incorporation into the pericellular area, the 
cytoplasmic rod-shaped structures were observed after differentiation of the transfected myoblasts. 
Formation of endogenous actin aggregates and poor incorporation into filamentous structure of stress 
fibres was the dominant features of the G53ins-β-TM mutant in the transfected myoblasts. Nice 
integration of the mutant TM into sarcomeric structures was found in transfected myotubes with G53ins-
β-TM mutant, although the mutant produced diffuse cytoplasmic staining at the far end of the myotubes. 
Finally, the N202K mutant formed clouds around the nucleus and in the cytoplasm with diffuse staining 
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and formation of small aggregates. In transfected myotubes the thin filaments appeared extremely 
thickened, resulting in huge accumulations of polymerized actin that disrupt actin filaments.  
 
Phenotypes observed in C2C12 transfected with mutant β-TMEGFP 
Transfection of mutant β-TMs into C2C12 was performed to compare the behaviour of the mutants in two 
different cell models. In contrast to human cells, where the various β-TM mutants behaved differently, 
the corresponding β-TM mutants resulted in similar features in transfected C2C12 cells. Intense EGFP 
aggregates co-localized with endogenous actin, mainly at the pericellular area of the cells, was the most 
striking abnormality by all β-TM mutants in C2C12 myoblasts and myotubes. 
Discussion  
The TPM2 mutations caused different morphological phenotypes in transfected cells, suggesting that 
mutations affect specific TM-binding interaction and/or function that invoke distinct structural changes 
within α-helical coiled-coil dimer or thin filament. Furthermore, the β-TM mutants behaved differently in 
human transfected myoblasts and myotubes. This may indicate that defects observed in transfected 
myoblasts are in vitro defects rather than direct association to the molecular mechanisms of the mutant 
isoforms. 
Although, our human tissue culture model did not recapitulate the pathological features observed in 
patient muscle biopsies the results may demonstrate a primary trigger for myopathy associated with 
TPM2 mutations. This may not be surprising, because the phenotypes observed in muscle biopsies from 
NM patients either taken from multiple sites or at different time points, are not similar[36-39]. Changes in 
morphological features are not only influenced by the mutations in different cellular environment. Other 
variable factors including hormone statue, compositions of sarcomeric proteins and TM isoforms, 
dynamic turnover, filament stoichiometry, ratio of the mutant variant, could also determine the 
differences between different cellular environments. This is further supported by the differences observed 
between phenotypes in transfected human and C2C12 cells. Thus, specific morphological abnormality 
might be associated with specific mutants under similar cellular conditions, but also influenced by 
underlying physiological contexts, which determine the cellular condition. 
 
Paper IV: MuRF1 and MuRF3 mutations cause a new protein aggregate myopathy and 
cardiomyopathy. 
Patient 
A 60-year old man was diagnosed with hypertrophic cardiomyopathy at the age of 20 years and he 
developed progressive muscle weakness in the four limbs, rigidity of the spine, scapular winging and 
mild respiratory involvement.  
Muscle morphology 
Muscle biopsy revealed fibre size variability, with atrophic in some fibre, mild endomysial fibrosis and 
predominance of type I fibres with distinctive subsarcolemmal homogeneous accumulations. The 
accumulations seemed as single or multiple well defined lesions in edges of muscle fibre. The inclusions 
were faintly basophilic on HE stain, light green with the modified trichrome, and were negative with PAS 
and congo red staining. The immunoractivity of the inclusions was positive for slow myosin, myomesin, 
M-line protein, MuRF3 and faint FHL immunoreactivity in fibre regions corresponding to the inclusions. 
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The inclusions were negative for filamentous actin, desmin, myotilin, c filamin, dystrophin, telethonin, α-
actinin, or tropomyosin.  
Electron microscopy 
The inclusions were abnormally oriented, consisting of fragments of sarcomeres with preserved A-bands 
and M-lines but lacking I-bands and Z-lines with varied length and width under the sarcolemma. 
Additionally, the thick filaments were scattered, fragmented and randomly oriented in some fibres.  
Genetic findings 
The sequencing of genomic DNA from a patient from a three-generation family from Spain revealed a 
homozygous nonsense mutation in TRIM63 and a heterozygous missense mutation in TRIM54. The 
appearance of both variants was examined in seven additional members of the family by sequencing and 
RFLP analyses. Several members of the family carried either TRIM63 or TRIM54. The RFLP and 
sequence analyses excluded the TRIM63 and TRIM54 sequence variants in 400 control chromosomes.  
RT-PCR, sequencing, immunoblotting and immunofluorescence studies on muscle tissue and cultured 
myoblast 
The transcript level of TRIM63 was not detected in muscle tissue or cultured cells from the patient. 
Additionally, the expression of MuRF1 at the protein level was examined by immunoblotting and 
immunofluorescence.  The western blot analysis indicated the absence of full size or truncated protein in 
the patient. The immunoblot analysis further indicated an increased in the content of MyHCs in the 
skeletal muscle tissue of the patient. This result may imply that the degradation of MyHCs via UPS is 
disrupted due to the absent of MuRF1 expression. The immunofluorescence confirmed the results 
obtained from immunoblot analysis of skeletal muscle tissue and cultured myoblasts from the patient. 
The expression of MuRF3 was confirmed by immunofluorescence and immunoblot analyses of skeletal 
muscle tissue as well as the cultured myoblasts from the patient. MuRF3 was accumulated with other 
proteins in the subsarcolemmal regions of many fibres. 
The immunostaining of α-tubulin in skeletal muscle and cultured myoblasts from the patient showed 
abnormal and scattered formation of aggregates in the periphery of fibres and severe distraction of the 
microtubule network. However, the level of the α-tubulin expression in patient muscle tissue was similar 
to that in the normal control muscle tissue, indicating that the mutation in MuRF3 affects the structure 
and organisation of microtubule rather than the expression level.  
The immunostaining of several sarcomeric proteins revealed the presence of the individual proteins, 
however the normal myofibrillar organization was lacking. The myofibrillar showed a primitive pattern of 
localization resembled to that of nascent myofibrillar.  
Transfection assay 
The transfection of wild-type TRIM63 was performed to examine whether the abnormal structure of 
microtubule network and defects in myofibrillogenesis are associated with the absence of MuRF1. 
Transfection of the wild-type TRIM63 resulted in nuclear and cytoplasmic localization of the fusion 
MuRF1EGFP protein and formation of microtubule networks. Furthermore, transfection of wild-type 
TRIM63 induced differentiation and elongation of myoblasts from the patient.  
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Transfection assay in the human myoblasts was performed to assess the effects of TRIM54 mutation. 
While the transfection of the wild-type TRIM54 was well-tolerated, the mutation induced formation of 
abnormal cytoplasmic thickened filamentous structures. The filamentous structures co-localized with the 
endogenous MuRF1 and microtubule filaments, indicating the pathogenic effect of the mutant MuRF3.  
Discussion 
The three MuRF genes, TRIM63, TRIM55 and TRIM54 encode highly homologous ring finger proteins, 
MuRF1, MuRF2 and MuRF3 respectively. These proteins have various physiological functions in 
skeletal and heart muscles [20]. The MuRF proteins play an important role in linking myofibril 
components with microtubules, intermediate filaments and nuclear factors [40]. Moreover, they function 
as E3 ubiquitin ligases in ubiquitin mediated muscle protein turnover to regulate protein degradation and 
gene expression in muscle tissues [21, 22]. MuRF1 and MuRF3 are E3 ubiquitin ligases that catalyse the 
degradation of slow/beta MyHC and MyHC IIa via the UPS in striated muscle[23]. 
 
The muscle pathology of the patient showed subsarcolemmal inclusions corresponding to thick filament-
associated proteins including slow myosin, myomesin and M-line protein, and absent of thin-filament and 
Z-line-associated proteins. In addition, EM analysis confirmed the results obtained from the muscle 
morphological analyses, indicating that inclusions contain fragments of sarcomeres with preserved M 
lines and A-bands but lacking Z-lines and I-bands. The accumulations of the proteins found in the muscle 
biopsy may reflect a defective degradation system that is likely to be caused by deficient E3 ligases 
MuRF1 and MuRF3.  
Our in vitro studies highlighted the essential role of MuRF1 in the formation of stable microtubule 
networks and myoblasts differentiation by acting as the transient scaffolds of myofibril assembly. The 
transfected myoblasts from the patient with the wild-type TRIM63 resulted in the formation of 
microtubule networks, in addition to promotion of myogenesis. These results indicate the association of 
deficient MuRF1 expression with abnormal formation of microtubule structures and defect in 
myofibrillogenesis.  
Previous studies have revealed the association of MuRF3 with formation of cellular microtubule, 
myogenic differentiation and myotube formation [40-42]. Our result from cellular studies further 
confirmed the importance of MuRF3 for the stability and formation of microtubule structure. Expression 
of mutant MuRF3 in control myoblasts resulted in formation of cytoplasmic aberrant filamentous 
structures, demonstrating a dominant negative effect of the TRIM54 mutation.  
The clinical, morphological, genetic and cellular models, in this study suggest that both MuRF1 and 
MuRF3 proteins functionally cooperate in striated muscle. 
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5 GENERAL CONCLUSIONS 
Mutations in sarcomeric proteins are important causes of cardiac and skeletal muscle diseases. Given 
their structural and functional roles in sarcomere contraction, it is not surprising that defects in sarcomeric 
proteins will affect muscle function. However, the primary effect of defective sarcomeric proteins on 
sarcomere formation and contractility, and their relation to muscle cell morphology are not completely 
understood for a number of the diseases. In this thesis, the disease-causing genes in an infant with a new 
unexpected myopathy and a family with cardiomyopathy and skeletal myopathy and their consequences 
are described. In addition, we used human tissue-culture cells to understand the pathogenesis and cellular 
mechanisms underlying a group of sarcomeric myopathies.  
In paper I, we investigated an infant with a fatal cardiomyopathy and an unexpected skeletal muscle 
myopathy. In this patient, we identified a homozygous mutation in the gene encoding the cardiac isoform 
of myosin binding protein C (MyBPC3). The expression of cardiac MyBPC, restricted to abnormal 
muscle fibres, indicated that the muscle pathology and unexpected skeletal myopathy was caused by a 
dominate-negative effect by ectopic expression of mutant MyBPC3.  
Many of the sarcomeric components of striated muscle exist as families of similar isoforms, which are 
developmentally regulated and differentially expressed in a tissue-specific manner in cardiac, slow and 
fast muscle. An important step in trying to understand how mutations in specific sarcomeric proteins 
might affect muscle function is to address the sequential employment and functional compensation of 
different isoforms of sarcomeric proteins during myogenesis. In paper II, we investigated the expression 
profile of a panel of sarcomeric components with a focus on proteins associated with a group of 
congenital disorders. We demonstrated that human skeletal muscle cultured cells are an appropriate tool 
to study developmental stages of myofibrillogenesis. The early and uniform expression of several of 
sarcomeric proteins suggested their impact on the developmental mechanisms involved in the initial 
stages of myofibril assembly, differentiation and formation of muscle. Many proteins involved in muscle 
diseases are detected in the stages of skeletal muscle cell differentiation that can be reached in vitro. This 
indicated that myoblasts isolated from patients with a mutation in one of the investigated sarcomeric 
genes might be an invaluable tool to analyze the effects of these mutations on sarcomere structure and 
formation. It would provide us new insights into development of muscle to indicate whether these 
diseases are disorders of myofibrillogenesis and muscle development. 
 
Transfection of mouse myoblasts has extensively been used to explore effects of sarcomeric gene 
mutations, because human myoblasts are more difficult to transfect. However, the use of human cells 
would be more relevant when studying human myopathies. In paper III, we established means to 
successfully transfect human myoblasts. We used this model to examine the sole consequences of amino 
acid alteration in the mutated beta tropomyosin, associated with different morphological features, and to 
find hints about which properties of the mutants are likely to cause the morphological changes.  Data 
from our human tissue culture model suggested the properties of β-TM mutants, which may be 
considered as the basis for the histological changes seen in muscle biopsies of patients and give us clues 
regarding the primary trigger for myopathy. We demonstrated that compared to mouse myoblasts 
(C2C12), human cells are environment closer to the reality in human skeletal muscle and more reliably 
mimic the disease conditions. In addition, we have demonstrated that histopathological phenotype 
associated with β-TM mutants may be accounted for the variable response to the cellular environment 
influenced by physiological context, in combination with the time course of expression of mutant protein 
rather than the alteration of amino acid itself.  
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In paper IV, we investigated a patient in a three-generation family with hypertrophic cardiomyopathy and 
progressive muscle weakness. Sequence analyses demonstrated that the patient was homozygous for a 
MuRF1 null mutation and heterozygous for a MuRF3 mutation. Muscle specific ring finger proteins 
MuRF1 and MuRF3 encoded by TRIM63 and TRIM54, respectively, are microtubule-associated proteins 
that localize to the sarcomeric M-band and Z-line. Association of MuRF with microtubules is required for 
its stability and myogenesis. MuRF1 and MuRF3 both are E3 ubiquitin ligases that mediate degradation 
of MyHCs via the ubiquitin proteasome system. The muscle pathological features included 
subsarcolemmal deposition of myosin and aberrant distribution of microtubules. Electron microscopy 
revealed peculiar accumulation of thick filament-like sarcomere fragments lacking Z-line and thin 
filaments beneath the sarcolemma and between apparently normal myofibrils. Differentiation of cultured 
myotubes from patient indicated perturbed myofibrillogenesis and an abnormal organization of the 
microtubule network. Transfection with wild-type MuRF1 induced organization of normal microtubule 
network and initiation of myofibrillogenesis in cultured myoblasts from the patient. Transfection of 
control myoblasts with mutant but not wild-type MuRF3 induced the formation of cytoplasmic irregular 
filamentous structures that co-localized with endogenous MuRF1 and alpha-tubulin demonstrating the 
pathogenic effect of MuRF3 missense mutation. 
 
Clinical, genetic and cellular investigations suggested that both proteins functionally cooperate in striated 
muscle. MuRF1 and MuRF3 work together in muscle differentiation, likely through stabilization of 
microtubule, regulation of protein degradation and maintaining titin M-line integrity. In addition, the 
hypothesis from paper II was confirmed in paper IV, where myoblasts isolated from patients with 
mutations in genes expressing muscle specific proteins showed to be an invaluable tool to analyze the 
effects of these mutations on sarcomere structure and myofilaments formation. 
 
 
 
 
 
 
 
 
 
 
24 
6 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Det finns olika former av muskelsjukdomar, och gemensamt för dessa är att de förorsakar muskelsvaghet 
och därmed försämrad rörelseförmåga. De flesta studerade muskelsjukdomar orsakas av mutationer som 
stör viktiga muskelproteiner, men just vilket protein som är skadat är i många fall ännu okänt. Vidare, för 
sjukdomar där mutationen är känd, behövs fortsatt forskning för att förstå hur mutationen påverkar 
muskelfunktionen och sjukdomsförloppet. Varje muskel uppbyggd av ett antal muskelbuntar som omges 
av ett bindvävslager och i sin tur består varje muskelbunt av ett visst antal muskelceller, som kallas 
muskelfibrer. En muskelcell är uppbyggd av mindre komponenter, nämligen muskelfibriller som ligger 
vid sidan om varandra och är tvärrandiga i normalt mikroskop. Fibrillerna är uppbyggda av långa kedjor 
av sarkomerer, den kontraktila delen av cellen som konstruerad av två typer av filamenter den tjocka 
filament (myosin filament) och den tunna filament (aktin filament).  
Skelettmuskulatur har förmåga att förnya sig i samband med fysisk skada eller muskel atrofi vid en 
muskelsjukdom. Formningen av muskulära vävnaden är en komplex process som sätter igång med hjälp 
av satellit celler och äger rum vid vuxen muskel regenerering och kännetecknas av vissa ändringar i 
muskel cell morfologi och cytoarkitektur. Satellit celler är en inaktiv muskel stem cell som ligger mellan 
basmembranet och muskelfibriller. De kan utvinnas från muskelbiopsier och användas som ett värdefullt 
verktyg för cell kultur studier av sjukdomarnas patogenes eller de inledande skedena av 
muskelutvecklingen. 
I två delarbeten i avhandlingen har vi identifierad genetiska orsaker till två nya hjärt- och 
muskelsjukdomar. Vi identifierade ett oväntat skelett muskelsjukdom förorsakad av en recessiv 
trunkerade mutation som stör den hjärtmuskel varianten av myosin bindande protein C (MyBP-C). MyBP 
C som är viktig för sarkomerstrukturen. Vi dessutom identifierade och karakteriserade en ny hjärt- och 
muskelsjukdom förorsakad av mutationer som stör funktionen och struktur av två varianter av muskel 
RING zinc finger protein familj (MuRF). Identifiering av genetiska orsaker till nya muskelsjukdomar är 
grunden till diagnostik, inklusive prenataldiagnostik och behandling. 
I studie av normal muskelbiologi i odlade humana muskelceller, vi följde cellerna från ”stamcell-stadiet” 
mot differentiering till kontraktila muskelceller. Resultatet från sådan studie visade i vilken ordning olika 
former av sarkomerproteiner byggs in i sarkomeren, vilket kunde vidare klargöra betydelsen av enskilda 
proteiner för sarkomerbildningen när muskel sjukdomen är orsakad av defekt i dessa proteiner.  
Genom genetisk manipulation etablerade vi sjukdomsmodellen för tropomyosin (TM)-relaterade 
sjukdomar i humana muskelceller. Vi fokuserade på muskelsjukdomar som är förorsakad av mutationer 
som stör funktionen eller struktur av beta-TM. TM ger stabilitet till aktinfilament i sarkomeren, och 
genom interaktion med andra proteiner är den central för att kontrollera kalciumrelaterad 
muskelkontraktion. Mutationer i beta-tropomyosin (beta-TM) leder till olika kliniska och morfologiska 
fenotyper. Vi ville uppnå en bättre förståelse av underliggande sjukdomsmekanismer och hur 
mutationerna leder till sjukdomsutveckling och studerade hur mutationerna påverkar sarkomerbildningen. 
Humana muskelceller odlades och transfekterades med beta-TM som bär på liknande mutationer som 
orsakar muskelsjukdomar hos patienter. Vidare transfekterade celler differentierades för att kunna studera 
effekten av den specifika mutationen under muskelcellutvecklingen. Målet var att kartlägga hur 
muskelsvikt uppstår på molekylär och cellbiologisk nivå för att kunna förstå patogenesen av dessa 
sjukdomar. Vi kunde identifiera de första molekylära ändringarna som händer i sarkomerstrukturen. 
 
 
 
 
25 
7 ACKNOWLEDGEMENTS 
It is a great pleasure to thank everyone who helped me during my preparation and completion of this 
study. I would like to show my gratitude to: 
Associated Professor Homa Tajsharghi my supervisor for her scientific guidance, encouragement and 
help throughout the research project.  
Professor Anders Oldfors my co-supervisor for his expert knowledge in muscle pathology, support and 
enthusiasm. 
 Associated Professor Ali-Reza Moslemi for his help and skillful experience in cell culturing and 
molecular genetics. 
Monica Jacobsson, Lili Seifi, Gabriella Almen, Anna-Carin Ericsson for helping me with valuable 
technical assistance, caring and for always having a spare time. 
Johanna Nilsson, Sara Ross and Carola Hedberg for consolation and positive attitude. 
Karin Rahl Thank you for good collaborations, your devotion, laughter and all good times. Love you and 
wish you the best.                                            
 Gyöngyvér Máthé Thank you for always being there when I need help and support, thank you for your 
kindness, thoughtfulness, compassion, laughter and all good times after work and weekends. Love you 
and wish you the best. 
Mehrnaz thank you dear for your help, gentleness and for all lunches at Amica. Love you and wish you 
the best 
Malgorzata Pokrzywa for good collaborations and support. 
Julia Fernandez,Maria Smedh and Carolina Tängemo for professional and valuable help with confocal 
microscopy. 
Eva Lyche for excellent secretarial assistance. 
Ulric Pedersen for valuable help with Photoshop program. 
The personnel at the department of pathology for a good working environment. 
Lilas Ali Thank you for all lunches, talks, jokes and laughter. 
My dearest sister and friend Wissam, Thank God for having such a wonderful sister. You have always 
been my rock in this life. Love you very much and thank you for your endless care, help, support, 
encouragement, understanding and last but not least your delicious food. 
 
 
 
26 
8 REFERENCES 
 
 
1. Yusuf F, Brand-Saberi B: Myogenesis and muscle regeneration. Histochemistry and cell biology 2012, 
138(2):187-199. 
2. Charge SB, Rudnicki MA: Cellular and molecular regulation of muscle regeneration. Physiological 
reviews 2004, 84(1):209-238. 
3. Le Grand F, Rudnicki MA: Skeletal muscle satellite cells and adult myogenesis. Current opinion in cell 
biology 2007, 19(6):628-633. 
4. Aziz A, Sebastian S, Dilworth FJ: The origin and fate of muscle satellite cells. Stem cell reviews 2012, 
8(2):609-622. 
5. Scharner J, Zammit PS: The muscle satellite cell at 50: the formative years. Skeletal muscle 2011, 
1(1):28. 
6. Turner NJ, Badylak SF: Regeneration of skeletal muscle. Cell and tissue research 2012, 347(3):759-774. 
7. DiMario JX: Myogenesis: Methods and Protocols; 2011. 
8. Kang JS, Krauss RS: Muscle stem cells in developmental and regenerative myogenesis. Current opinion 
in clinical nutrition and metabolic care 2010, 13(3):243-248. 
9. Tajbakhsh S: Skeletal muscle stem cells in developmental versus regenerative myogenesis. Journal of 
internal medicine 2009, 266(4):372-389. 
10. Sambasivan R, Tajbakhsh S: Skeletal muscle stem cell birth and properties. Seminars in cell & 
developmental biology 2007, 18(6):870-882. 
11. Sasson DA: Stem Cells and Cell Signalling in Skeletal Myogenesis, vol. Volym 11 av Advances in 
Developmental Biology and Biochemistry. Elsevier; 2002. 
12. Curci R, Battistelli M, Burattini S, D'Emilio A, Ferri P, Lattanzi D, Ciuffoli S, Ambrogini P, Cuppini R, 
Falcieri E: Surface and inner cell behaviour along skeletal muscle cell in vitro differentiation. Micron 
(Oxford, England : 1993) 2008, 39(7):843-851. 
13. Simionescu A, Pavlath GK: Molecular mechanisms of myoblast fusion across species. Advances in 
experimental medicine and biology 2011, 713:113-135. 
14. Kontrogianni-Konstantopoulos A, Catino DH, Strong JC, Bloch RJ: De novo myofibrillogenesis in 
C2C12 cells: evidence for the independent assembly of M bands and Z disks. American journal of 
physiology Cell physiology 2006, 290(2):C626-637. 
15. Schultheiss T, Lin ZX, Lu MH, Murray J, Fischman DA, Weber K, Masaki T, Imamura M, Holtzer H: 
Differential distribution of subsets of myofibrillar proteins in cardiac nonstriated and striated 
myofibrils. The Journal of cell biology 1990, 110(4):1159-1172. 
16. Rhee D, Sanger JM, Sanger JW: The premyofibril: evidence for its role in myofibrillogenesis. Cell 
motility and the cytoskeleton 1994, 28(1):1-24. 
17. Ten Broek RW, Grefte S, Von den Hoff JW: Regulatory factors and cell populations involved in 
skeletal muscle regeneration. Journal of cellular physiology 2010, 224(1):7-16. 
18. Gregorio CC, Antin PB: To the heart of myofibril assembly. Trends in cell biology 2000, 10(9):355-362. 
19. Luther PK: Three-dimensional structure of a vertebrate muscle Z-band: implications for titin and 
alpha-actinin binding. Journal of structural biology 2000, 129(1):1-16. 
20. Gregorio C, Perry C, McElhinny A: Functional properties of the titin/connectin-associated proteins, 
the muscle-specific RING finger proteins (MURFs), in striated muscle. 2005(6):389-400. 
21. Freemont PS: RING for destruction? Current biology : CB 2000, 10(2):R84-87. 
22. Glass D, Roubenoff R: Recent advances in the biology and therapy of muscle wasting. Annals of the 
New York Academy of Sciences 2010, 1211:25-36. 
23. Fielitz J, Kim MS, Shelton JM, Latif S, Spencer JA, Glass DJ, Richardson JA, Bassel-Duby R, Olson EN: 
Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 
and 3. The Journal of clinical investigation 2007, 117(9):2486-2495. 
24. Kontrogianni-Konstantopoulos A, Ackermann MA, Bowman AL, Yap SV, Bloch RJ: Muscle giants: 
molecular scaffolds in sarcomerogenesis. Physiological reviews 2009, 89(4):1217-1267. 
25. Gordon AM, Homsher E, Regnier M: Regulation of contraction in striated muscle. Physiological 
reviews 2000, 80(2):853-924. 
26. Schiaffino S, Reggiani C: Molecular diversity of myofibrillar proteins: gene regulation and functional 
significance. Physiological reviews 1996, 76(2):371-423. 
27. Schiaffino S, Reggiani C: Fiber types in mammalian skeletal muscles. Physiological reviews 2011, 
91(4):1447-1531. 
28. Engel A, Franzini-Armstrong, Clara: Myology: basic and clinical: London: McGraw-Hill, cop; 1994. 
 
 
27 
29. Moslemi AR, Lindberg C, Nilsson J, Tajsharghi H, Andersson B, Oldfors A: Glycogenin-1 deficiency and 
inactivated priming of glycogen synthesis. The New England journal of medicine 2010, 362(13):1203-
1210. 
30. Sanger JW, Kang S, Siebrands CC, Freeman N, Du A, Wang J, Stout AL, Sanger JM: How to build a 
myofibril. Journal of muscle research and cell motility 2005, 26(6-8):343-354. 
31. Ehler E, Gautel M: The sarcomere and sarcomerogenesis. Advances in experimental medicine and 
biology 2008, 642:1-14. 
32. van der Ven PF, Schaart G, Jap PH, Sengers RC, Stadhouders AM, Ramaekers FC: Differentiation of 
human skeletal muscle cells in culture: maturation as indicated by titin and desmin striation. Cell 
and tissue research 1992, 270(1):189-198. 
33. van der Ven PF, Furst DO: Assembly of titin, myomesin and M-protein into the sarcomeric M band in 
differentiating human skeletal muscle cells in vitro. Cell structure and function 1997, 22(1):163-171. 
34. Sanger JW, Wang J, Fan Y, White J, Sanger JM: Assembly and dynamics of myofibrils. Journal of 
biomedicine & biotechnology 2010, 2010:858606. 
35. Sanger JW, Chowrashi P, Shaner NC, Spalthoff S, Wang J, Freeman NL, Sanger JM: Myofibrillogenesis 
in skeletal muscle cells. Clinical orthopaedics and related research 2002(403 Suppl):S153-162. 
36. Tajsharghi H, Ohlsson M, Lindberg C, Oldfors A: Congenital myopathy with nemaline rods and cap 
structures caused by a mutation in the beta-tropomyosin gene (TPM2). Archives of neurology 2007, 
64(9):1334-1338. 
37. Ilkovski B, Nowak KJ, Domazetovska A, Maxwell AL, Clement S, Davies KE, Laing NG, North KN, 
Cooper ST: Evidence for a dominant-negative effect in ACTA1 nemaline myopathy caused by 
abnormal folding, aggregation and altered polymerization of mutant actin isoforms. Human 
molecular genetics 2004, 13(16):1727-1743. 
38. Shafiq SA, Dubowitz V, Peterson Hde C, Milhorat AT: Nemaline myopathy: report of a fatal case, with 
histochemical and electron microscopic studies. Brain : a journal of neurology 1967, 90(4):817-828. 
39. Ryan MM, Ilkovski B, Strickland CD, Schnell C, Sanoudou D, Midgett C, Houston R, Muirhead D, 
Dennett X, Shield LK et al: Clinical course correlates poorly with muscle pathology in nemaline 
myopathy. Neurology 2003, 60(4):665-673. 
40. Spencer JA, Eliazer S, Ilaria RL, Jr., Richardson JA, Olson EN: Regulation of microtubule dynamics and 
myogenic differentiation by MURF, a striated muscle RING-finger protein. The Journal of cell 
biology 2000, 150(4):771-784. 
41. Chang W, Webster DR, Salam AA, Gruber D, Prasad A, Eiserich JP, Bulinski JC: Alteration of the C-
terminal amino acid of tubulin specifically inhibits myogenic differentiation. The Journal of biological 
chemistry 2002, 277(34):30690-30698. 
42. Gundersen GG, Khawaja S, Bulinski JC: Generation of a stable, posttranslationally modified 
microtubule array is an early event in myogenic differentiation. The Journal of cell biology 1989, 
109(5):2275-2288. 
 
  
 
 
28 
 
 
 
 
 
 
 
 
 
 
 
